Abstract
The human high mobility group (HMG) protein (HMGI-C) belongs to the HMG family of
architectural transcription factors which are expressed only during embryonic development,
and not in normal adult tissues. Considerable interest has recently been shown in
HMGI-C and its expression in a variety of neoplastic tissues, whereas no expression could
be found in normal tissue adjacent to the tumour. So far, no data is available on
the expression of HMGI-C in the peripheral blood of patients with solid tumours. In this study we analysed
the expression of HMGI-C in peripheral blood samples of 61 patients with breast cancer and 35 healthy donors
using a haemi-nested reverse transcriptase–polymerase chain reaction (RT-PCR) technique.
No HMGI-C could be detected in any of the healthy donors' samples. In the three prognostic
groups according to the Nottingham Prognostic Score, the proportion of patients expressing
HMGI-C differed significantly (P=0.001). The worse the prognosis was, the more patients expressed HMGI-C. This is the first report on the expression of HMGI-C in the peripheral blood of patients with breast cancer and our data suggest that
this expression is correlated with a poor prognosis.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- High-mobility-group chromosomal proteins.Prog. Nucl. Acid Res. Mol. Biol. 1996; 54: 35-100
- HMGI(Y) and HMGI-C dysregulation.Adv. Anat. Pathol. 1999; 6: 237-246
- A novel downstream positive regulatory element mediating transcription of the human high mobility group protein (HMGI-C) gene.FEBS Lett. 1999; 457: 429-436
- Molecules in focus — the high mobility group protein HMGI-C.Int. J. Biochem. Cell. Biol. 1998; 30: 761-766
- NF-kappaB-mediated activation is enhanced by the architectural factor HMGI-C.Nucl. Acids Res. 1998; 26: 1433-1439
- HMGI-C expression patterns in human tissues — implications for the genesis of frequent mesenchymal tumors.Am. J. Pathol. 1996; 149: 775-779
- Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C.Nature. 1995; 376: 771-774
- Intron 3 of HMGI-C is the most frequent target of chromosomal aberrations in human tumors and has been conserved basically for at least 30 million years.Cancer Genet. Cytogenet. 1998; 103: 175-177
- Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells.Mol. Cell. Biol. 1995; 15: 1545-1553
- Expression of HMGI-C, a member of the high mobility group family, in a subset of breast cancers.Mol. Carcinogenesis. 1997; 19: 153-156
- HMGI-C expression patterns in non-small lung cancer and surrounding tissue.Anticancer Res. 1998; 18: 3327-3330
- HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells.Leukemia Lymphoma. 1997; 26: 603-607
- The expression of the high mobility group HMGI(Y) proteins correlates with the malignant phenotype of human thyroid neoplasias.Oncogene. 1995; 10: 1307-1314
- A fibroadenoma with a t(4;12) (q27;q15) affecting the HMGI-C gene, a member of the high mobility group protein gene family.Breast Cancer Res. Treat. 1996; 38: 299-303
- HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas.Oncogene. 1996; 12: 515-521
- Misexpression of wild-type and truncated isoforms of the high mobility group I proteins HMGI-C and HMGI(Y) in uterine leiomyomas.Am. J. Pathol. 1999; 155: 1535-1542
- Expression and cDNA cloning of human HMGI-C phosphoprotein.Biochem. Biophys. Res. Commun. 1994; 201: 63-70
- Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy.Breast Cancer Res. Treat. 1992; 22: 221-227
- Determination of high mobility group I (Y) expression levels in colorectal neoplasias.Cancer Res. 1999; 59: 1169-1174
- A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.Br. J. Cancer. 1996; 74: 573-578
Article info
Publication history
Accepted:
July 4,
2000
Received in revised form:
June 5,
2000
Received:
February 14,
2000
Identification
Copyright
© 2000 Elsevier Science Ltd. Published by Elsevier Inc. All rights reserved.
